UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,784	03/28/2006	Luz Sanguansri	024219-0104	5502
	7590 08/18/200 LARDNER LLP	EXAMINER		
SUITE 500	T NIVI	WARE, DEBORAH K		
3000 K STREE WASHINGTO		ART UNIT	PAPER NUMBER	
			1651	
			MAIL DATE	DELIVERY MODE
			08/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Applicati	on No.	Applicant(s)				
		10/573,78	34	SANGUANSRI ET AL.				
		Examine		Art Unit				
		DEBBIE H		1651				
Period fo	The MAILING DATE of this communication a or Reply	appears on the	cover sheet with the c	correspondence ad	ddress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) \	Responsive to communication(s) filed on 15	5 January 200	10					
, —	Responsive to communication(s) filed on <u>15 January 2009</u> . This action is FINAL . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
٥/ا	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	on of Claims							
4)🖂	Claim(s) <u>1-15</u> is/are pending in the applicati	on.						
	4a) Of the above claim(s) <u>12-15</u> is/are withdrawn from consideration.							
	is/are allowed.							
	6)⊠ Claim(s) <u>1-11</u> is/are rejected.							
-	Claim(s) is/are objected to.							
-	Claim(s) are subject to restriction and	d/or election r	equirement.					
Applicat	ion Papers							
9)☐ The specification is objected to by the Examiner.								
-			□ objected to by the I	Examiner.				
10)☑ The drawing(s) filed on is/are: a)☑ accepted or b)☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.05(a).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice (3) Inform	t(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate				

Application/Control Number: 10/573,784 Page 2

Art Unit: 1651

DETAILED ACTION

Claims 1-15 are pending.

Response to Amendment

The amendments filed January 15, 2009 and May 6, 2009, have been received and entered. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Response to Arguments

The amendments have initiated a new search and discovery of a new reference which has been applied below. The previous rejections have been removed.

Foreign Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on March 28, 2006, was received and entered of record. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Response to Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-11, drawn to a probiotic in oil.

Group II, claim(s) 12-15, drawn to a powder consisting of bacteria and an oligosaccharide.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Each of the compositions comprise different ingredients and the mechanism of encapsulation is not the same.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/573,784 Page 4

Art Unit: 1651

Applicant's election without traverse of Group I, claims 1-11, in the reply filed on July 25, 2008, is acknowledged.

Claims 12-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on July 25, 2008.

Claim Rejections - 35 USC § 102/103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-11 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over newly cited van Lengerich (US 6500463), cited on enclosed PTO-892 Form.

Claims are drawn to encapsulated probiotic.

van Lengerick teaches an encapsulated microorganism (e.g. probiotic) by the combination of a protein and a carbohydrate by mixing a water dispersible probiotic microorganism in an aqueous suspension of a protein and a carbohydrate, note abstract and bridging col. 8-9, lines 65-67 and lines 1-10, respectively. Whey protein, at col. 13, line 67 is disclosed. Prebiotics and probiotics are disclosed at col. 14, line 56. The carbohydrate can be a reducing sugar group. The material is a film forming substance, note col. 6, line 50. Also the carbohydrate can be starch (col. 9, line 3). The bacteria is Lactobacillus, note col. 13, line 1. Low temperature is used to encapsulate probiotic bacteria. Note col. 5, line 20. The encapsulant can be dried, note col. 6, line 48. Also it

can be in powdered form, note col. 5, line 30. Oil can be optionally added, note col. 8, lines 1-2, and the encapsulant can be a probiotic.

The claims are identical to the teachings of van Lengerick and are, therefore, considered to be anticipated by the cited disclosure. However, in the alnterantive that there is some unidentified claimed characteristic for which is not disclosed by van Lengerick then the difference is considered to be so slight as to render the claims obvious over the cited disclosure of van Lengerick. It would have been obvious to combine the disclosed protein and carbohydrate to provide for an encapsulated probiotic as claimed because the teachings of van Lengerick clearly teach, or at least suggest, the same. Each of the claim features are disclosed or suggested as discussed above. In the absence of persuasive evidence to the contrary the claims are alternatively rendered prima facie obvious over van Lengerick.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

All claims fail to be patentably distinguishable over the state of the art discussed above and cited on the enclosed PTO-892 and/or PTO-1449. Therefore, the claims are properly rejected.

The remaining references listed on the previously enclosed PTO-892 and/or PTO-1449 are cited to further show the state of the art.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBBIE K. WARE whose telephone number is (571)272-0924. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/573,784 Page 8

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/DKW/
Deborah K. Ware
Examiner
Art Unit 1651
/David M. Naff/
Primary Examiner, Art Unit 1657